Galantamine is a novel post-exposure therapeutic against lethal VX challenge

Toxicology and Applied Pharmacology

Volumn 240, Issue 2, 2009, Pages 166-173

  Hilmas, Corey J ^a   Poole, Melissa J ^b   Finneran, Kathryn ^a   Clark, Matthew G ^c   Williams, Patrick T ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Electroencephalography; Galantamine; Muscle paralysis; Nerve agent; Neuroprotection; Survival

Indexed keywords

GALANTAMINE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DIAPHRAGM PARALYSIS; DOSE RESPONSE; DRUG MECHANISM; ELECTROENCEPHALOGRAM; GUINEA PIG; LETHALITY; MALE; MUSCLE FATIGUE; MUSCLE TETANIC CONTRACTION; MUSCLE TONE; NONHUMAN; PROTECTION; SEIZURE; SURVIVAL RATE;

ACETYLCHOLINESTERASE; ANIMALS; ANTIDOTES; ATROPINE; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; DIAPHRAGM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; ERYTHROCYTES; GALANTAMINE; GUINEA PIGS; MALE; MUSCLE FATIGUE; MUSCLE TONUS; NEUROTOXICITY SYNDROMES; ORGANOTHIOPHOSPHORUS COMPOUNDS; PARALYSIS; PHRENIC NERVE; PRALIDOXIME COMPOUNDS; SEIZURES; TIME FACTORS;

ANIMALIA; CAVIA;

EID: 70349235301     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.029     Document Type: Article

References (33)

1. Albuquerque E.X., Pereira E.F.R., Aracava Y., Oliveira W.M., Randall W.R., Hamilton T.A., Kan R.K., Romano Jr. J.A., and Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 13220-13225
2. Arias E., Ales E., Gabilan N.H., Cano-Abad M.F., Villarroya M., Garcia A.G., and Lopez M.G. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46 (2004) 103-114
3. Berman H.A., and Decker M.M. Kinetic, equilibrium, and spectroscopic studies on dealkylation ("aging") of alkyl organophosphonyl acetylcholinesterase. Electrostatic control of enzyme topography. J. Biol. Chem. 261 (1986) 10646-10652
4. Berry W.K., and Davies D.R. The use of carbamates and atropine in the protection of animals against poisoning by 1,2,2-trimethylpropylmethylphosphonofluoridate. Biochem. Pharmacol. 19 (1970) 927-934
5. Caldwell R.W., Lowensohn H.S., Chryssanthis M.A., and Nash C.B. Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity. Fundam. Appl. Toxicol. 12 (1989) 432-441
6. Cohen M.I. Neurogenesis of respiratory rhythm in the mammal. Physiol. Rev. 59 (1979) 1105-1173
7. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. J. Clin. Pract. 57 (2003) 219-223
8. Dawson R.M. Review of oximes available for treatment of nerve agent poisoning. J. Appl. Toxicol. 14 (1994) 317-331
9. Deshpande S.S., Sheridan R.E., and Adler M. Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 35 (1997) 433-445
10. DiGiovanni C. Domestic terrorism with chemical or biological agents: psychiatric aspects. Am. J. Psych. 156 (1999) 1500-1505
11. Feaster, S.R., Gordon, R.K., Doctor, B.P., Clark, C.R., Maxwell, D.M., Lenz, D.E., 2000. Unprocessed whole blood cholinesterase levels: WRAIR protocol development and validation. Proc. 2000 US Army Medical Defense Bio Science Rev., 1024-1032.
12. French M.C., Wetherell J.R., and White P.D.T. The reversal by pyridostigmine of neuromuscular block produced by soman. J. Pharm. Pharmacol. 31 (1979) 290-294
13. Gordon J.J., Leadbeater L., and Maidment M.P. The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol. Appl. Pharmacol. 43 (1978) 207-216
14. Green D.M., Muir A.W., Stratton J.A., and Inch T.D. Dual mechanism of the antidotal action of atropine-like drugs in poisoning by organophosphorus anticholinesterases. J. Pharm. Pharmacol. 29 (1977) 62-64
15. Hilmas, C.J., Apland, J.P., Deshpande, S.S., Haigh, J., Gordon, R., Adler, M., 2006. Pyridostigmine bromide pretreatment protects against soman-induced lethality in the guinea pig. USAMRICD Technical Report (ICD 06-19).
16. Hoskins B., Fernando J.C., Dulaney M.D., Lim D.K., Liu D.D., Watanabe H.K., and Ho I.K. Relationship between the neurotoxicities of Soman, Sarin, and Tabun, and acetylcholinesterase inhibition. Toxicol. Lett. 30 (1986) 121-129
17. Kihara T., Sawada H., Nakamizo T., Kanki R., Yamashita H., Maelicke A., and Shimohama S. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun. 325 (2004) 976-982
18. Lilienfeld S. Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8 (2002) 159-176
19. Marino M.T., Schuster B.G., Brueckner R.P., Lin E., Kaminskis A., and Lasseter K.C. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J. Clin. Pharmacol. 38 (1998) 227-235
20. Maxwell D.M., Brecht K.M., Lenz D.E., and O'Neill B.L. Effect of carboxylesterase inhibition on carbamate protection against soman toxicity. J. Pharmacol. Exp. Ther. 246 (1988) 986-991
21. McDonough J.H., and Shih T.M. Pharmacological modulation of soman-induced seizures. Neurosci. Biobehav. Rev. 17 (1993) 203-215
22. Morita H., Yanagisawa N., Nakajima T., Shimizu M., Hirabayashi H., Okudera H., Nohara M., Midorikawa Y., and Mimura S. Sarin poisoning in Matsumoto, Japan. Lancet 346 (1995) 290-293
23. Ohbu S., Yamashina A., Takasu N., Yamaguchi T., Murai T., Nakano K., Matsui Y., Mikami R., Sakurai K., and Hinohara S. Sarin poisoning on Tokyo subway. South. Med. J. 90 (1997) 587-593
24. Pazdernik T.L., Nelson S.R., Cross R., Churchill L., Giesler M., and Samson F.E. Effects of antidotes on soman-induced brain changes. Arch. Toxicol., Suppl. 9 (1986) 333-336
25. Pereira E.F.R., Hilmas C., Santos M.D., Alkondon M., Maelicke A., and Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol. 53 (2002) 479-500
26. RAC (Research Advisory Committee on Gulf War Veterans' Illness). Gulf War Illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations (2008), US Government Printing Office, Washington, DC November
27. Shih T.M., and McDonough J.H. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication. Arch. Toxicol. 74 (2000) 165-172
28. Sogorb M.A., Vilanova E., and Carrera V. Future applications of phosphotriesterases in the prophylaxis and treatment of organophosporus insecticide and nerve agent poisonings. Toxicol. Lett. 151 (2004) 219-233
29. Taylor P. Anticholinesterase agents. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Bilman A.G. (Eds). The Pharmacological Basis of Therapeutics (1996), New York, McGraw-Hill 131-149
30. Thomsen T., and Kewitz H. Selective inhibition of human acetylcholinesterase by galantamine in vitro and in vivo. Life Sci. 46 (1990) 1553-1558
31. Thomsen T., Bickel U., Fischer J.P., et al. Stereoselectivity of cholinesterase inhibition by galantamine and tolerance in humans. Eur. J. Clin. Pharm. 39 (1990) 603-605
32. Thomsen T., Zendeh B., Fischer J.P., et al. In vitro effects of various cholinesterase inhibitors on acetyl- and butyryl-cholinesterases of healthy volunteers. Biochem. Pharmacol. 41 (1991) 139-141
33. Wright P.G. An analysis of the central and peripheral components of respiratory failure produced by anticholinesterase poisoning in the rabbit. J. Physiol. (Lond.) 126 (1954) 52-70